Expression of Bcr-Abl in hematopoietic stem cells is sufficient to cause chronic myeloid leukemia (CML) and tyrosine kinase inhibitors (TKI) induce molecular remission in the majority of CML patients. | Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia